Zhang X, Zhang Y, Peng D, Shi X, Zhang Z, Wang J
Oncol Lett. 2024; 27(4):187.
PMID: 38486945
PMC: 10938287.
DOI: 10.3892/ol.2024.14319.
Zhang Y, Zhang W, Huang D, Wang Y, Hu H, Zhi T
BMC Pediatr. 2023; 23(1):617.
PMID: 38053080
PMC: 10699076.
DOI: 10.1186/s12887-023-04258-w.
Han Y, Chang J, Lin L, Zhou C, Zhu J, Wu H
Cancer Rep (Hoboken). 2023; 6(10):e1875.
PMID: 37503828
PMC: 10598254.
DOI: 10.1002/cnr2.1875.
Jiang M, Hu X, Qian K, Yang P, Tang Y, Wang P
Transl Pediatr. 2022; 11(7):1267-1273.
PMID: 35958006
PMC: 9360815.
DOI: 10.21037/tp-22-205.
Imaya M, Muramatsu H, Narita A, Yamamori A, Wakamatsu M, Yoshida T
Cancer Med. 2022; 11(9):1956-1964.
PMID: 35233973
PMC: 9089216.
DOI: 10.1002/cam4.4529.
Clinical impact of primary tumour ImIBG response to induction chemotherapy in children with high-risk neuroblastoma.
Szychot E, Morgenstern D, Chopra M, Sorrentino S, Arthurs O, Sebire N
Int J Clin Oncol. 2021; 27(1):253-261.
PMID: 34626287
DOI: 10.1007/s10147-021-02039-y.
Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma.
Szanto C, Cornel A, Tamminga S, Delemarre E, de Koning C, van den Beemt D
Cancers (Basel). 2021; 13(9).
PMID: 33926057
PMC: 8123570.
DOI: 10.3390/cancers13092096.
METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study.
Zhuo Z, Lu H, Zhu J, Hua R, Li Y, Yang Z
Mol Ther Nucleic Acids. 2020; 22:17-26.
PMID: 32891980
PMC: 7484523.
DOI: 10.1016/j.omtn.2020.08.009.
Association of image-defined risk factors, tumor resectability, and prognosis in children with localized neuroblastoma.
Zhang A, Pan C, Xu M, Wang X, Ye Q, Gao Y
World J Pediatr. 2019; 15(6):572-579.
PMID: 31342464
DOI: 10.1007/s12519-019-00274-y.
Surgical removal of adult recurrent neuroblastoma located in the posterior mediastinum and retroperitoneum: A case report.
Ma X, Yang Y, Wang Z, Sun W, Zhang D, Wu B
Medicine (Baltimore). 2018; 97(50):e13642.
PMID: 30558057
PMC: 6320002.
DOI: 10.1097/MD.0000000000013642.
High-Risk Neuroblastoma Treatment Review.
Smith V, Foster J
Children (Basel). 2018; 5(9).
PMID: 30154341
PMC: 6162495.
DOI: 10.3390/children5090114.
rs11655237 C>T confers neuroblastoma susceptibility in Chinese population.
Zhang Z, Chang Y, Jia W, Zhang J, Zhang R, Zhu J
Biosci Rep. 2018; 38(1).
PMID: 29339420
PMC: 5803493.
DOI: 10.1042/BSR20171667.
gene polymorphisms reduce neuroblastoma risk in Chinese children.
Zhang J, Zhuo Z, Wang J, He J, Yang L, Zhang D
Oncotarget. 2017; 8(53):91343-91349.
PMID: 29207648
PMC: 5710928.
DOI: 10.18632/oncotarget.20514.
polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.
Zhang J, Lin H, Wang J, He J, Zhang D, Qin P
Oncotarget. 2017; 8(39):65620-65626.
PMID: 29029458
PMC: 5630358.
DOI: 10.18632/oncotarget.20018.
Incorporation of high-dose I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.
Lee J, Lee S, Cho H, Ma Y, Yoo K, Sung K
J Hematol Oncol. 2017; 10(1):108.
PMID: 28511709
PMC: 5432997.
DOI: 10.1186/s13045-017-0477-0.
Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma.
Buhagiar A, Ayers D
Anal Cell Pathol (Amst). 2015; 2015:150634.
PMID: 26258008
PMC: 4516851.
DOI: 10.1155/2015/150634.
High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas.
Ramani P, Sowa-Avugrah E, May M
Virchows Arch. 2015; 467(3):319-27.
PMID: 26199132
DOI: 10.1007/s00428-015-1806-8.
High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
Ramani P, Taylor S, Miller E, Sowa-Avugrah E, May M
J Histochem Cytochem. 2015; 63(6):397-407.
PMID: 25711230
PMC: 4872195.
DOI: 10.1369/0022155415576966.
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.
Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini G
PLoS One. 2014; 9(12):e114696.
PMID: 25502557
PMC: 4263607.
DOI: 10.1371/journal.pone.0114696.
Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
Mazloom A, Louis C, Nuchtern J, Kim E, Russell H, Allen-Rhoades W
Int J Radiat Oncol Biol Phys. 2014; 90(4):858-62.
PMID: 25245583
PMC: 5107988.
DOI: 10.1016/j.ijrobp.2014.07.019.
